A novel tissue repair technology developed at the University of New South Wales presents a tremendous licensing opportunity for a company with existing expertise in the tissue repair and wound healing sector.

UNSW scientists have developed a proprietary laser activated polysaccharide adhesive system that has been demonstrated in vitro, ex vivo, and in vivo. This polysaccharide adhesive system is an alternative to albumin solders and other biological glues, and alleviates many of their associated disadvantages.




Please watch our UNSW YouTube Clip introducing this technology

More Information and Contact Details: PDF version of Non-Confidential Disclosure Document

An opportunity exists for an industrial bioprocessing company to collaborate with UNSW to develop a manufacturing process for the production of glutathione from the yeast Saccharomyces cerevisiae.

More Information and Contact Details: PDF version of Non-Confidential Disclosure Document

Researchers from the School of Biotechnology and Biomolecular Science at UNSW have developed a platform technology that could be used to express exogenous DNA. Applications may include the production of ethanol from waste plant material and also other valuable metabolites.

More Information and Contact Details: PDF version of Non-Confidential Disclosure Document

A licensing opportunity exists to develop a simple, fast and accurate HLA tissue typing test that is cost effective, simple to use, and doesn’t require specialist staff to perform or interpret results.

More Information and Contact Details: PDF version of Non-Confidential Disclosure Document

We have identified a protein called seipin which is involved in lipid metabolism, and can be manipulated and used as a potential tool to silence a gene and affect lipid metabolism in people with lipodystrophy, those who are obese, patients with Type II diabetes, and those HIV positive patients receiving anti-retroviral therapy (for which lipodystrophy is a side effect). We can also provide a mutant yeast strain to screen for small molecules that inhibit activity of human seipin.

More Information and Contact Details: PDF version of Non-Confidential Disclosure Document

NewSouth Innovations (NSi), the commercialisation office of UNSW has formed Nanomed to manufacture materials and devices for the healthcare sector using our patented Atomised Rapid Injection for Solvent Extraction (ARISE) technology.
ARISE is second generation, super critical fluid (SCF) solvent extraction technology which generates from pharmaceutical mixtures aerodynamic, nanomolecular particulates with improved surface area and particle distribution size. Nanoparticles can accelerate the identification of new drug delivery technology and medical devices.
The key application of ARISE is in the generation of therapeutics (proteins, peptides, organic compounds) for pulmonary delivery, such as Inhalable Insulin.

More Information and Contact Details: PDF version of Non-Confidential Disclosure Document

Cucurbiturils (Qs) are a family of rigid, chemically and thermally robust container molecules that are superior to cyclodextrins.
Qs are self-assembling, macrocyclic compounds that are synthesized from the acid catalysed condensation of formaldehyde with glycoluril.
Qs resemble open-ended barrels, providing a hydrophobic cavity with different modes of binding. The variety of sizes available (Q5 to Q10) and their hollow structure provide a wide range of possible applications as carriers for absorption or delivery of guest molecules in a number of different environments.

More Information and Contact Details: PDF version of Non-Confidential Disclosure Document